Aurobindo Pharma to stress on research effort

HYDERABAD: Aurobindo Pharma Ltd, one of the leading pharmaceutical companies, is planning to increase its focus on regulated markets and give more impetus to its research efforts. The company’s two active pharma ingredients (API) hubs and two formulation hubs are geared up for approvals from regulated markets.
The green field API project at Pydibheemavaram near Srikakulam and revamped unit at Hyderabad would be the backbone of Aurobindo Pharma with global scale of manufacturing, the company said in its annual report.
According to the growth plan, the company would develop a broad portfolio of drug master files (DMFs) and abbreviated new drug applications (ANDAs) through non-infringing processes and intellectual properties and become a significant player in the generics market, especially in the regulated markets. “Priority is being given to fast moving products that can seize opportunities in the post product patent regime. Filing ANDAs for products for which process patents have been granted would add to the marketing muscle,� the company said.
Aurobindo Pharma is a leader in the semi synthetic penicillin (SSPs) and cephalosporins. “After creating a name in producing APIs and intermediates, Aurobindo Pharma sees major growth in speciality generic formulations business,� the company said.
Currently, over 70 drugs in the area of SSPs, cephalosporins, anti AIDS and speciality anti-infectives and over 30 drugs in the area of life style diseases drive the API businesses and its growth. The company has submitted registration dossiers pharmaceutical raw materials (DMFs) for 10 products and has started registration procedures for 17 more products, it said.
Aurobindo also has its operations in China. Aurobindo (Datong) Bio-Pharma Company Ltd, the company’s venture, is located in Datong in China. The unit has fermentation facilities to manufacture Penicillin G Potassium and 6-APA, key raw material for semi synthetic penicillin. Currently, Aurobindo is importing large quantity of Penicillin G. This new capacity would supplement its import, the company said.